To verify this assumption, a CRISPR-Cas9 approach was used to abrogate SLC2A1 or SLC2A3 in the RKO or SW620 CRC cell line, respectively (Fig. 4a). The gene discussed is SLC2A3; the disease is colorectal carcinoma.